Some well-known cancer biomarkers include PSA (Prostate-Specific Antigen) for prostate cancer, HER2 for breast cancer, and CA-125 for ovarian cancer. Recently, liquid biopsies, which detect circulating tumor DNA (ctDNA) in the blood, have emerged as promising tools for various cancers, providing a non-invasive method to monitor disease progression and treatment response.
